Review of the impact of molecular analysis on the therapy of medulloblastoma

Abstract

Medulloblastoma (MB) is a brain tumor composed of distinct molecularly defined subgroups. Recent advances in genomics and transcriptomics have revealed >12 subtypes within the previously identified four subgroups. Molecular classification has improved clinical outcome predictions and facilitated introduction of risk-adjusted therapy. Newer subtyping of MB has the potential to rapidly guide the development of clinical trials that further explore risk-adjusted therapies. This review summarizes recent advances in the molecular characterization of medulloblastoma and evaluates subgroup directed treatment.

Keywords

• Medulloblastoma
• Molecular classification
• Risk adapted therapy